Spravato® for depression that won't lift.
An FDA-approved nasal spray when antidepressants haven't worked.
Being Health accepts
As low as $10 per session
Eligible patients pay as little as $10 per session through the Spravato® withMe rebate program, which lowers your share of treatment costs. Your actual price depends on your insurance and deductible.
What is Spravato® (Esketamine)?
Spravato® is an FDA-approved treatment that offers relief for adults with treatment-resistant depression (TRD) and major depressive disorder (MDD) with suicidal thoughts or behaviors.
Delivered as a nasal spray under clinical supervision, Spravato® works differently than traditional antidepressants—and it's the only ketamine-based therapy covered by many major insurance plans.
What conditions can Spravato® treat?
Spravato® (esketamine) intranasal spray is FDA-approved for use alone or in combination alongside an oral antidepressant to treat adults who have been diagnosed with the following conditions
Treatment-Resistant Depression (TRD)
Depression that does not respond to two or more antidepressant medications.
Major Depressive Disorder (MDD) + Suicidality
Depression with acute suicidal ideation or behavior.
Discover the benefits of Spravato® treatment
Spravato® has been shown in numerous studies to provide rapid improvement in depressive symptoms in people with treatment-resistant depression.
Rapid Antidepressant
Effect
Spravato® can offer immediate relief from depressive symptoms, and reduce depression relapse rates.
Medical Supervision You Can Trust
Board-certified psychiatrists and emergency medicine physicians oversee every session in our comfortable Manhattan clinic, ensuring your safety and comfort throughout treatment.
FDA-Approved & Covered by Insurance
Spravato® is FDA approved and covered by many major insurance plans. That means expert care, without the full out-of-pocket cost.
Experience Spravato® at our New York City space
We offer in-clinic Spravato® treatment at our Manhattan location, designed with healing in mind.
What our patients say
"I had looked into ketamine, but the cost was overwhelming. Finding out Spravato was covered by my insurance changed everything."
Christine, 25
"I spent years trying different medications with little change. This was the first treatment that helped me feel a shift. It didn’t happen overnight, but after a few sessions, I finally began to feel like myself again."
Kar, 48
"What made a big difference wasn’t just the treatment - it was the environment. I felt safe, heard, monitored. Being Health’s team walked me through every step, and I never once felt like I was doing this alone."
Jake, 36
"I didn't know how much treating my mental health also meant caring for my body. Doing Spravato alongside therapy and nutrition support helped me feel more stable."
Irene, 55
Spravato® Treatment at Being Health
Our Spravato® program involves a comprehensive evaluation with a Being Health prescriber to determine eligibility, followed by the recommended Spravato® protocol.
Interventional Psychiatry Consultation
60 minutes
FAQs
Is Spravato® covered by insurance?
Yes, Spravato® (esketamine) is FDA-approved and often covered by insurance, including most commercial plans. Coverage typically requires that certain clinical criteria are met, such as a diagnosis of treatment-resistant depression and a history of trying multiple antidepressants without sufficient improvement.
During your initial consultation, a Being Health psychiatrist will assess if Spravato® is right for you. If so, we’ll review your insurance coverage, determine any out-of-pocket costs, handle prior authorizations, and manage any paperwork for you.
Am I eligible for Spravato® treatment?
You may be eligible for Spravato® (esketamine) if you’re an adult and meet certain clinical criteria. Eligibility is typically based on insurance and medical guidelines, but most patients qualify through one of the pathways below.
General requirements:
- You are 18 years or older
- The treatment must be done at a REMS (the FDA’s Risk Evaluation and Mitigation Strategies) certified doctor's office or clinic such as Being Health
- You have medical and psychiatric clearance to receive Spravato
- You must be able to stay on-site for at least 2 hours after each dose for monitoring
Pathway 1: Treatment-Resistant Depression (TRD) - for individuals whose depression has not improved with standard treatments. You may qualify if:
- You have moderate to severe major depressive disorder, confirmed by a standardized scale such as a PHQ-9.
- You’ve tried at least two antidepressants (at adequate dose and duration) without meaningful improvement.
- You have medical and psychiatric clearance to receive Spravato
- You do not have medical or psychiatric conditions that are contraindicated for the use of Spravato
Pathway 2: Depression with acute suicidal thoughts - for adults who are experiencing an active mental health crisis. You may qualify if:
- You have major depressive disorder (MDD) with current suicidal thoughts or behaviors
- Treatment is used short-term to help stabilize symptoms
- Spravato® is part of a broader safety and care plan (it does not replace hospitalization if needed)
- You do not have medical or psychiatric conditions that are contraindicated for the use of Spravato
Who may not be eligible:
- Spravato® may not be appropriate if you have certain medical conditions (such as specific blood vessel disorders or severe liver disease), are pregnant or breastfeeding, or have an untreated substance use disorder.
Eligibility and coverage varies by insurance plan. Our team will help review your history and benefits to determine if Spravato® is right for you.
Is Spravato® FDA approved?
Yes, Spravato® was first approved by the FDA in 2019 for use alongside an oral antidepressant to treat treatment-resistant depression (TRD) in adults—typically defined as depression that hasn’t improved after trying at least two antidepressants. Spravato® is also approved for adults with major depressive disorder (MDD) who are experiencing acute suicidal thoughts or behavior.
In early 2025, the FDA expanded its approval, allowing Spravato® to be used on its own, making it the first and only FDA-approved monotherapy for adults with TRD.
How does Spravato® work?
Spravato® works differently from common oral antidepressants. Rather than targeting serotonin, it targets the NMDA receptor, a part of the brain’s glutamate system involved in mood regulation and neuroplasticity. This unique mechanism can potentially lead to rapid improvement in symptoms and has been shown to be uniquely effective in individuals experiencing depressive symptoms that haven’t responded to other forms of treatment.
Do I have to go off antidepressants to receive Spravato® treatments?
No, you don’t need to stop taking your current antidepressant. Spravato® was originally approved to be used in combination with an oral antidepressant and was recently approved for use on its own. If Spravato® is right for you, our clinical team will review your current medications to ensure they’re safe and compatible with your treatment plan.
How do I know if Spravato® is right for me?
Spravato® may be an option if you’re an adult living with treatment-resistant depression—typically defined as depression that hasn’t improved after trying at least two antidepressant medications. It may also be appropriate if you’re experiencing major depressive disorder (MDD) with acute suicidal thoughts or behavior.
At Being Health, one of our psychiatrists will meet with you for an initial consultation to evaluate your symptoms, treatment history, and overall health. If Spravato® is a good fit, we’ll guide you through every step, from insurance authorization to ongoing treatment and monitoring.
What symptoms and conditions might improve with Spravato® treatment?
Spravato® is primarily used to treat treatment-resistant depression—a form of depression that hasn’t responded well to other medications. People often report improvements in symptoms like persistent sadness, hopelessness, fatigue, low motivation or even suicidal thoughts. It may also help with emotional numbness, anxiety related to depression, and difficulty enjoying daily life.
If you’ve been feeling stuck despite trying multiple treatments, Spravato® may offer a new path toward relief and healing.
What are the risks and potential side effects of Spravato®?
Like any medication, Spravato® can have side effects. The most common include dissociation (feeling disconnected from yourself or your surroundings), dizziness, nausea, sleepiness, increased blood pressure, and a sense of floating or spinning. These effects usually occur shortly after treatment and tend to wear off the same day.
In more severe circumstances it can cause slowed breathing and sedation. It also carries a risk of abuse/misuse. And Spravato® is not safe in individuals where a significant elevation in blood pressure would be dangerous, such as individuals with an aneurysm, stroke, intracerebral hemorrhage, and significant cardiovascular disease. It is also not approved for use during pregnancy. Additionally, like all antidepressant medications, Spravato® has an FDA warning that antidepressant medications may increase suicidal thoughts and actions in some people 24 years of age and younger.
Because of these potential risks and side effects, Spravato® is only available through a certified treatment center under the FDA’s Risk Evaluation and Mitigation Strategy (REMS) program. This means it must be administered in a clinical setting with medical supervision who will carefully monitor your response to ensure your safety and comfort throughout treatment.
See important safety information
Is Spravato® addictive?
Spravato® (esketamine) has the potential for misuse or dependence, which is why it’s only available through a clinically monitored setting like Being Health, under medical supervision. However, when used as prescribed and administered in a clinical setting, the risk of addiction is considered low.
Our clinical team follows all safety protocols and monitors each patient closely before, during, and after treatment to ensure it’s used responsibly and effectively.
